Charles Loftin

Contact Information

347 Bio Pharm Complex
789 South Limestone Street
Lexington, KY 40536-0596

Phone: 859-323-9892

Fax: 859-257-7564

Contact by email


  • Associate Professor
    Department of Pharmaceutical Sciences

Charles Loftin, Ph.D.

Dr. Loftin received a Ph.D. in Toxicology in 1995 from the University of North Carolina at Chapel Hill and a B.S. in Pharmacy in 1989 from Auburn University. Before joining the University of Kentucky, Dr. Loftin was a Research Fellow with the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina.

Research Interests

Dr. Loftin's lab studies the functions of prostanoids, which are lipid mediators formed by most tissues and best known for producing inflammation. Prostanoids are synthesized by the cyclooxygenases that are better known as COX-1 and COX-2. The COX enzymes are targets of nonsteroidal anti-inflammatory drugs, such as aspirin and ibuprofen, and the COX-2-selective inhibitor celecoxib. By utilizing pharmacological inhibitors of the COX enzymes together with mice genetically deficient in either COX-1 or COX-2, Dr. Loftin's lab has identified a variety of different physiological and pathophysiological processes that are dependent on either COX-1 or COX-2. These include prenatal and postnatal vascular development, protection against pathogen-induced atherosclerosis, adipose tissue differentiation, vascular remodeling associated with aortic aneurysm initiation and progression, and vascular smooth muscle cell phenotypic modulation. The goal of this work is to identify targets down-stream of the COX isoforms that will lead to the development of medications with novel therapeutic benefit and which lack the adverse effects of currently available COX inhibitors.

Selected Publications/Presentations

  • Tiano HF, Loftin CD, Lee CA, Dunson DB, Rogan EG, Smart RC, Morham SG, Langenbach R. Deficiency of Either Cyclooxygenase-1 or Cyclooxygenase-2 Alters Epidermal Differentiation and Reduces Mouse Skin Tumorigenesis. Cancer Research; 62: 3395-3401, 2002.
  • Loftin CD, Trivedi DB and Langenbach R. Cyclooxygenase-1-Selective Inhibition Delays Labor in Mice and Lacks the Adverse Fetal and Neonatal Effects of Cyclooxygenase-2-Selective inhibition. Journal of Clinical Investigation; 110(4):549-57, 2002
  • Kim K, Baek SJ, Flake GP, Loftin CD, Calvo BF and Eling TE. Expression and regulation of NAG-1, a anti-tumorigenic protein, in human and mouse colorectal tissue. Gastroenterology; 122(5):1388-98, 2002.
  • Xu H, Izon DJ, Loftin CD, and Spain LM. The COX-2 Inhibitor NS-398 Causes T Cell Developmental Disruptions Independent of COX-2 Enzyme Inhibition. Cellular Immunology; 214(2):184-93, 2001.
  • Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM, Goulet JL, Smithies O, Koller BH and Langenbach R. Failure of Ductus Arteriosus Closure and Remodeling in Neonatal Mice Deficient in Cyclooxygenase-1 and Cyclooxygenase-2. Proceedings of the National Academy of Sciences; 98(3):1059-1064, 2001.
  • Langenbach R, Loftin CD, Lee C and Tiano H. Cyclooxygenase knockout mice - Models for elucidating isoform-specific functions. Biochemical Pharmacology; 58:1237-1246, 1999.
  • Langenbach R, Loftin CD, Lee C, Tiano H. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Annals of the New York Academy of Sciences; 889:52-61, 1999.
  • Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Davis BJ, Lee CA. Disruption of the mouse cyclooxygenase 1 gene. Characteristics of the mutant and areas of future study. Advances in Experimental Medicine and Biology; 407:87-92, 1997.
  • Chulada PC, Loftin CD, Winn VD, Young D, Tiano HF, Eling TE and Langenbach R. Relative activities of retrovirally expressed murine prostaglandin synthase-1 and -2 depend on the source of arachidonic acid. Archives of Biochemistry and Biophysics; 330(2):301-13, 1996.
  • Loftin CD and Eling TE. Prostaglandin synthase 2 expression in epidermal growth factor-dependent proliferation of mouse keratinocytes. Archives of Biochemistry and Biophysics; 330(2):419-29, 1996.
  • Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA and Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell; 83(3):473-82, 1995.
  • Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS and Smithies O. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell; 83(3):483-92, 1995.
page last modified: February 14 2014     

© University of Kentucky College of Pharmacy
Official Site of the University of Kentucky College of Pharmacy